Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity

Journal of Clinical Investigation

Volumn 123, Issue 6, 2013, Pages 2654-2662

  Ghosh, Arnab ^a   Dogan, Yildirim ^a   Moroz, Maxim ^a   Holland, Amanda M ^a   Yim, Nury L ^a   Rao, Uttam K ^a   Young, Lauren F ^a   Tannenbaum, Daniel ^a   Masih, Durva ^a   Velardi, Enrico ^a,b   Tsai, Jennifer J ^a   Jenq, Robert R ^a   Penack, Olaf ^c   Hanash, Alan M ^a   Smith, Odette M ^a   Piersanti, Kelly ^a   Lezcano, Cecilia ^d   Murphy, George F ^d   Liu, Chen ^e   Palomba, M Lia ^a   Sauer, Martin G ^f   Sadelain, Michel ^a   Ponomarev, Vladimir ^a   Van Den Brink, Marcel R M ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; GENE OVEREXPRESSION; GENETIC ENGINEERING; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGEN-PRESENTING CELLS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEK293 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84878541023     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66301     Document Type: Article

References (31)

1. Blazar BR, Murphy WJ, Abedi M. Advances in graftversus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
2. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
3. Brentjens RJ, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
4. + leukemias. Blood. 2012; 120(8):1633-1646.
5. Bendle GM, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565-570.
6. van Loenen MM, et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A. 2010;107(24):10972-10977.
7. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity. 2003;18(1):1-6.
8. Frew AJ, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A. 2008;105(32):11317-11322.
9. Sayers TJ, et al. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 2003; 102(1):303-310.
10. Sun K, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A. 2004;101(21):8120-8125.
11. Schmaltz C, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med. 2002; 8(12):1433-1437.
12. Na IK, et al. The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versushost disease. J Clin Invest. 2010;120(1):343-356.
13. Zakrzewski JL, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008;26(4):453-461.
14. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434(7029):88-93.
15. + T-cell responses through control of TRAIL expression. Blood. 2012;119(3):798-804.
16. Finnberg N, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol. 2005;25(5):2000-2013.
17. + T cells and apoptosis. PLoS One. 2012;7(3):e32874.
18. Sheridan JP, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277(5327):818-821.
19. Martinez-Lostao L, Marzo I, Anel A, Naval J. Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer. Biochem Pharmacol. 2012;83(11):1475-1483.
20. Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. J Immunol. 2011;187(6):3087-3095.
21. Brincks EL, Katewa A, Kucaba TA, Griffith TS, Legge KL. CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol. 2008;181(7):4918-4925.
22. + T cells protect against influenza infection. J Immunol. 2013;190(1):296-306.
23. Ramirez-Montagut T, et al. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease. J Immunol. 2007; 179(3):1669-1680.
24. + T cell repertoire. J Immunol. 2004;172(4):2324-2331.
25. Zakrzewski JL, et al. Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. Nat Med. 2006;12(9):1039-1047.
26. Hanash AM, et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood. 2011;118(2):446-455.
27. Dobrenkov K, et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med. 2008;49(7):1162-1170.
28. Takeda K, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cellmediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol. 2001; 214(2):194-200.
29. Waldman E, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107(4):1703-1711.
30. Holland AM, et al. Extrathymic development of murine T cells after bone marrow transplantation. J Clin Invest. 2012;122(12):4716-4726.
31. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.